Construction is nearly complete on the DHS's National Bio defense Analysis and Counter measures Center at Fort Detrick, Maryland, on a National Interagency Biodefense Campus that has lab facilities operated by the CDC, NIH, US Department of Agriculture (USDA), and DOD.
The existence of the National Interagency Biodefense Campus suggests that the federal government recognizes the importance of scientific collaboration, coordination, and communication in addressing issues of biosecurity. Yet according to fiscal year 2009 DHS budget documents, "A comprehensive understanding of how biodefense initiatives are coordinated at various levels of government and the private sector does not exist."
Evidence pointing toward inadequate oversight amid expansive growth in the number of biosafety research laboratories emerged during an Oc tober 2007 hearing of the House Subcommittee on Oversight and Investigations. Keith Rhodes of the Government Account ability Office (GAO) testified that no one agency is responsible for tracking the rapidly growing number of high-containment labs (BSL-3 and BSL-4) in the academic, state, and private sectors. In fact, the GAO review revealed that even the number of BSL-3 labs-where work is done on biological agents such as anthrax and West Nile virus-remains unknown.
Whatever the number, it is growing, and as the number of laboratories grows, the number of individuals handling dangerous biological agents grows as well, as does the potential for accidents. Unchecked expansion of laboratories with little federal oversight is a recipe for disaster, contended Edward Hammond of the Sunshine Project, a now defunct nongovernmental watchdog organization. He warned Congress that "the most likely source of a bioterrorist event in the US is a US biodefense lab."
In light of these concerns, the NIH initiated a Trans-Federal Task Force on Optimizing Biosafety Oversight. The task force, cochaired by the Department of Health and Human Services and USDA, includes representatives from the agencies responsible for managing biosafety risks. According to Mary Groesch, senior adviser for science policy in the Office of the Director at the NIH, the group is working quickly to identify gaps in current biosafety oversight, lay out potential options for addressing these issues, and develop recommendations for department leadership. Strategies under consideration include the development of mandatory federal biosafety standards and the centralization of federal biosafety authority.
"The time is ripe for something to be done," says Gigi Kwik Gronvall, senior associate at the Center for Biosecurity. "Biosafety failures have been more evident in the media, and this area has lots of eyes on it. If recommendations from the task force are reasonable, nothing should block action from being taken."
Gronvall emphasizes that one must remember that the greatest danger is for the people working with the patho gens. Centralizing oversight and authority in one office may help get more resources dedicated to improving bio safety, she said. "It is more im portant that recommendations take a bottom-up approach, focusing more on the people and the lab safety officers who directly oversee the work."
